Keywords: Ceftobiprole, Johnson & Johnson, Basilea, Janssen Cilag, CHMP, MRSA

Johnson & Johnson unit calls for re-examination of ceftobiprole, licensed from Basilea, submitted to CHMP

Article | 12 March 2010

Janssen-Cilag International NV, a subsidiary of US health care giant Johnson & Johnson, has submitted a request for re-examination of the negative opinion issued on February 18 by the European Committee for Medicinal Products for Human Use (CHMP) on the Marketing Authorization Application (MAA) for Zeftera (ceftobiprole) for the treatment of complicated skin and soft tissue infections (cSSTI).

The negative European regulatory opinion on ceftobiprole led Janssen-Cilag to return rights to the product they had been jointly developing over the past five years to originator Switzerland-based Basilea (The Pharma Letter February 22). Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in